Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients

Author(s): Amel G. Elsheredy, Abdulrahman H. Almaeen, Amany A. Ghazy*, Ghada F. Helaly, Ibrahim Amer, Haneen A. Ghazy and Tamer Haydara

Volume 20, Issue 8, 2020

Page: [1328 - 1335] Pages: 8

DOI: 10.2174/1871530320666200505113619

Price: $65

Abstract

Background: Single nucleotide polymorphisms (SNPs) of IL-28B and/or ICAM-1 could have a role in expecting a response from HCV infected patients to direct antiviral agents (DAAs).

Objective: The aim of the current study was to investigate the impact of IL-28B rs12979860 and rs8099917, and, ICAM-1 rs281437 SNPs on response to treatment with sofosbuvir + Daclatsvir ± Ribavirin, among HCV-infected Egyptian patients.

Methods: Whole blood genomic DNA was extracted from 120 participants (80 HCV-infected patients and 40 healthy volunteers). HCV-infected patients were subdivided into responders and nonresponders to DAAs. Liver function testing, anti-HCV antibodies, HCV-RNA viral load and HCV genotyping were performed. IL-28B and ICAM-1 SNPs were evaluated by real-time PCR.

Results: ALT and AST levels were significantly higher among non-responder HCV infected patients (P = 0.001*). 90% of the patients had HCV genotype 4a and the remaining 10% had 4l genotype. Allelic discrimination revealed that IL-28B rs12979860 T, IL-28B rs809917 T and ICAM-1 rs281437 C alleles were more frequent among HCV-infected patients (responders or non-responders) than controls. However, IL-28B rs8099917 G allele was more frequent among healthy controls. Regarding the response to DAAs treatment, HCV-infected patients with IL-28B rs8099917 GG genotype showed a significantly earlier viral response compared to those carrying TT alleles. ICAM-1 rs281437 CT alleles were non significantly more frequent among responders. However, IL-28B rs12979860 alleles did not show any difference.

Conclusion: Genotyping of IL-28B rs8099917 is a useful independent tool for expecting a response of Egyptian HCV-infected patients to DAAs.

Keywords: Hepatitis C virus, direct antiviral agents, IL-28B, ICAM-1 single nucleotide polymorphism, viral response.

« Previous Next »
Graphical Abstract

[1]
Sakhaee, F.; Ghazanfari, M.; Vaziri, F.; Jamnani, F.R.; Davari, M.; Gharibzadeh, S.; Fateh, R.; Abdolrahimi, F.; Dizaji, S.P.; Fateh, A.; Siadat, S.D. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect. Genet. Evol., 2017, 54, 330-337.
[http://dx.doi.org/10.1016/j.meegid.2017.07.023] [PMID: 28739427]
[2]
Bayomy Helal, H.E.; Yuonis, A.; Shaker, R.H.M.; Elawady, M.A. Prevalence of HCV Infection in Household Contacts of Chronic Liver Diseases Cases in Egypt. J. Environ. Public Health, 2018, 20182153537
[http://dx.doi.org/10.1155/2018/2153537]] [PMID: 30473711]
[3]
Das, D.; Pandya, M. Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis c therapy. Mini Rev. Med. Chem., 2018, 18(7), 584-596.
[http://dx.doi.org/10.2174/1389557517666170913111930] [PMID: 28901852]
[4]
Spengler, U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol. Ther., 2018, 183, 118-126.
[http://dx.doi.org/10.1016/j.pharmthera.2017.10.009] [PMID: 29024739]
[5]
European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J. Hepatol., 2015, 63(1), 199-236.
[http://dx.doi.org/10.1016/j.jhep.2015.03.025] [PMID: 25911336]
[6]
Tamori, A.; Kawada, N. HLA class II associated with outcomes of hepatitis B and C infections. World J. Gastroenterol., 2013, 19(33), 5395-5401.
[http://dx.doi.org/10.3748/wjg.v19.i33.5395] [PMID: 24023482]
[7]
Thomas, D.L.; Thio, C.L.; Martin, M.P.; Qi, Y.; Ge, D.; O’Huigin, C.; Kidd, J.; Kidd, K.; Khakoo, S.I.; Alexander, G.; Goedert, J.J.; Kirk, G.D.; Donfield, S.M.; Rosen, H.R.; Tobler, L.H.; Busch, M.P.; McHutchison, J.G.; Goldstein, D.B.; Carrington, M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461(7265), 798-801.
[http://dx.doi.org/10.1038/nature08463] [PMID: 19759533]
[8]
Asselah, T.; De Muynck, S.; Broët, P.; Masliah-Planchon, J.; Blanluet, M.; Bièche, I.; Lapalus, M.; Martinot-Peignoux, M.; Lada, O.; Estrabaud, E.; Zhang, Q.; El Ray, A.; Vidaud, D.; Ripault, M.P.; Boyer, N.; Bedossa, P.; Valla, D.; Vidaud, M.; Marcellin, P. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol., 2012, 56(3), 527-532.
[http://dx.doi.org/10.1016/j.jhep.2011.09.008] [PMID: 21951981]
[9]
Rizk, N.M.; Derbala, M.F. Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. Clin. Res. Hepatol. Gastroenterol., 2013, 37(3), 262-268.
[http://dx.doi.org/10.1016/j.clinre.2012.09.012] [PMID: 23137758]
[10]
Ea, R.; Aa, G.; Ag, E.S.; Ma, A. Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients. Egypt. J. Immunol., 2015, 22(2), 57-68.
[PMID: 28502145]
[11]
Helaly, G.F.; Elsheredy, A.G.; Bedewy, E.S.; Attia, N.M. Sequence heterogeneity in the core and NS5A region of hepatitis c virus (hcv) and il-28b polymorphisms in predicting treatment response among chronic HCV genotype 4 infected Egyptian patients. Int. J. Curr. Microbiol. Appl. Sci., 2017, 6(7), 2382-2398.
[http://dx.doi.org/10.20546/ijcmas.2017.607.282]
[12]
Ghazy, A.A.; El-Etreby, N.M. Relevance of HLA-DP/DQ and ICAM-1 SNPs among ovarian cancer patients. Front. Immunol., 2016, 7, 202.
[http://dx.doi.org/10.3389/fimmu.2016.00202] [PMID: 27252704]
[13]
Ghazy, A.A.; El-Sheredy, A.G.; Al-Din, K.M.; Khatab, M.; Abdel-Rahman, Z.A. The Effect of IP-10 Level and HLA-DP/DQ polymorphisms on response to nucleoside/nucleotide analogues treatment among hepatitis B Egyptian patients. Br. Microbiol. Res. J., 2016, 13(4), 1-11.
[http://dx.doi.org/10.9734/BMRJ/2016/24047]
[14]
Kirkpatrick, L.A.; Feeney, B.C. A simple guide to IBM SPSS statistics for version 20, . 2013.
[15]
Echeverría, N.; Chiodi, D.; López, P.; Sanchez Ciceron, A.; Angulo, J.; López-Lastra, M.; Silvera, P.; Canavesi, A.; Bianchi, C.; Colistro, V.; Cristina, J.; Hernandez, N.; Moreno, P. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol. J., 2018, 15(1), 40.
[http://dx.doi.org/10.1186/s12985-018-0946-2] [PMID: 29499724]
[16]
Zakaria, Z.A.; Knapp, S.; Hashem, M.; Zaghla, H.; Thursz, M.; Waked, I.; Abdelwahab, S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol. Res., 2019, 67(1), 123-133.
[http://dx.doi.org/10.1007/s12026-018-9035-2] [PMID: 30402710]
[17]
Elsheredy, A.G.; Ghazy, A.A.; Madkour, M.A. Study of Interleukin IL-28B rs12979860 and rs8099917 Polymorphisms among HBV Infected Egyptian Patients. Egypt. J. Med. Microbiol., 2017, 26(3), 45-51.
[http://dx.doi.org/10.12816/0046287]
[18]
Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; Sulkowski, M.; McHutchison, J.G.; Goldstein, D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461(7262), 399-401.
[http://dx.doi.org/10.1038/nature08309] [PMID: 19684573]
[19]
Khattab, H.; Fouad, A.; Hamza, M.; Mohey, M.A.; El-Akel, W.; Ghoneim, H.; Abul-Fotouh, A.; Esmat, G. Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. Arab J. Gastroenterol., 2015, 16(2), 50-53.
[http://dx.doi.org/10.1016/j.ajg.2015.06.004] [PMID: 26184441]
[20]
Kostadinova, L.; Shive, C.L.; Zebrowski, E.; Fuller, B.; Rife, K.; Hirsch, A.; Compan, A.; Moreland, A.; Falck-Ytter, Y.; Popkin, D.L.; Anthony, D.D. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathog. Immun., 2018, 3(1), 149-163.
[http://dx.doi.org/10.20411/pai.v3i1.242] [PMID: 30370392]
[21]
Derbala, M.; Rizk, N.; Shebl, F.; Alkaabi, S.; Eldweik, N.; John, A.; Sharma, M.; Yaqoob, R.; Almohanadi, M.; Butt, M.; Alejji, K. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J. Gastroenterol., 2012, 18(47), 7003-7008.
[http://dx.doi.org/10.3748/wjg.v18.i47.7003] [PMID: 23323000]
[22]
Antaki, N.; Bibert, S.; Kebbewar, K.; Asaad, F.; Baroudi, O.; Alideeb, S.; Hadad, M.; Abboud, D.; Sabah, H.; Bochud, P.Y.; Negro, F. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J. Viral Hepat., 2013, 20(1), 59-64.
[http://dx.doi.org/10.1111/j.1365-2893.2012.01621.x] [PMID: 23231085]
[23]
Hayashi, K.; Katano, Y.; Ishizu, Y.; Kuzuya, T.; Honda, T.; Ishigami, M.; Itoh, A.; Hirooka, Y.; Ishikawa, T.; Nakano, I.; Yoshioka, K.; Toyoda, H.; Kumada, T.; Goto, H. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. J. Gastroenterol. Hepatol., 2015, 30(1), 178-183.
[http://dx.doi.org/10.1111/jgh.12673] [PMID: 24995561]
[24]
Kawaoka, T.; Hayes, C.N.; Ohishi, W.; Ochi, H.; Maekawa, T.; Abe, H.; Tsuge, M.; Mitsui, F.; Hiraga, N.; Imamura, M.; Takahashi, S.; Kubo, M.; Tsunoda, T.; Nakamura, Y.; Kumada, H.; Chayama, K. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol., 2011, 54(3), 408-414.
[http://dx.doi.org/10.1016/j.jhep.2010.07.032] [PMID: 21112660]
[25]
Yu, M.L.; Huang, C.F.; Huang, J.F.; Chang, N.C.; Yang, J.F.; Lin, Z.Y.; Chen, S.C.; Hsieh, M.Y.; Wang, L.Y.; Chang, W.Y.; Li, Y.N.; Wu, M.S.; Dai, C.Y.; Juo, S.H.; Chuang, W.L. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology, 2011, 53(1), 7-13.
[http://dx.doi.org/10.1002/hep.23976] [PMID: 21254157]
[26]
Sticchi, L.; Di Biagio, A.; Rappazzo, E.; Setti, M.; De Rosa, G.; De Hoffer, L.; Nicolini, L.; Prinapori, R.; Bruzzone, B. Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. J. Prev. Med. Hyg., 2013, 54(2), 83-86.
[PMID: 24396987]
[27]
Fateh, A.; Aghasadeghi, M.R.; Keyvani, H.; Mollaie, H.R.; Yari, S.; Hadizade Tasbiti, A.R.; Ghazanfari, M.; Monavari, S.H. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment. Asian Pac. J. Cancer Prev., 2015, 16(5), 1873-1880.
[http://dx.doi.org/10.7314/APJCP.2015.16.5.1873] [PMID: 25773839]
[28]
Nadia, K.; Hicham, E.; Reda, T.M.; Nadia, T.; Elarbi, B.; Saâd, E.; Mimoun, Z.; Saâd, M. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. Gene, 2015, 568(1), 31-34.
[http://dx.doi.org/10.1016/j.gene.2015.05.010] [PMID: 25958342]
[29]
Xu, X.; Li, Y.M.; Ji, H.; Hou, C.Z.; Cheng, Y.B.; Ma, F.P. Changes of ECM and CAM gene expression profile in the cirrhotic liver after HCV infection: analysis by cDNA expression array. World J. Gastroenterol., 2005, 11(14), 2184-2187.
[http://dx.doi.org/10.3748/wjg.v11.i14.2184] [PMID: 15810090]
[30]
Zhang, X.Q.; Hong, X.J.; Bai, X.J. Susceptibility to active decompensated cirrhosis is associated with polymorphisms of intercellular adhesion molecule-1 (ICAM-1) in chronic HBV carriers. J. Viral Hepat., 2008, 15(3), 173-178.
[http://dx.doi.org/10.1111/j.1365-2893.2007.00931.x] [PMID: 18233990]
[31]
Constantini, P.E.M.; Graziadei, I.; Vogel, W. Icam-1 polymorphism: New risk factor for hepatocellular carcinoma in patients with chronic hepatitis C? J. Hepatol., 2000, 32(Suppl. 2), 93.
[http://dx.doi.org/10.1016/S0168-8278(00)80688-1]
[32]
Chen, T.P.; Lee, H.L.; Huang, Y.H.; Hsieh, M.J.; Chiang, W.L.; Kuo, W.H.; Chou, M.C.; Yang, S.F.; Yeh, C.B. Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development. Tumour Biol., 2016, 37(2), 2067-2074.
[http://dx.doi.org/10.1007/s13277-015-3992-z] [PMID: 26341495]
[33]
Cai, G.; Ma, X.; Zou, W.; Huang, Y.; Zhang, J.; Wang, D.; Chen, B. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis. Gene, 2014, 546(1), 117-123.
[http://dx.doi.org/10.1016/j.gene.2013.07.049] [PMID: 23933413]

Rights & Permissions Print Cite
Article Metrics
34
© 2024 Bentham Science Publishers | Privacy Policy